Appendix B: Acronyms
Updated
Reviewed
| Acronym | Name |
|---|---|
| ACTG | AIDS Clinical Trials Group |
| AMP | Adolescent Master Protocol |
| ANRS | National Agency for AIDS Research (France) |
| ARROW | AntiRetroviral Research fOr Watoto |
| ATHENA | AIDS Therapy Evaluation in the Netherlands |
| ATLAS | Antiretroviral Therapy as Long-Acting Suppression |
| BAN | Breastfeeding, Antiretrovirals, and Nutrition |
| BRIGHTE | A Multi-arm, Phase 3, Randomized, Placebo Controlled, Double Blind Clinical Trial to Investigate the Efficacy and Safety of Fostemsavir (BMS-663068/GSK3684934) in Heavily Treatment Experienced Subjects Infected With Multi-drug Resistant HIV-1 |
| CALIBRATE | Study to Evaluate the Safety and Efficacy of Lenacapavir (GS-6207) in Combination With Other Antiretroviral Agents in People Living With HIV |
| CAPELLA | A Phase 2/3 Study to Evaluate the Safety and Efficacy of Long-Acting Capsid Inhibitor GS-6207 in Combination With an Optimized Background Regimen in Heavily Treatment Experienced People Living With HIV-1 Infection With Multidrug Resistance |
| CHAPAS | Children with HIV in Africa—Pharmacokinetics and Acceptability of Simple second-line antiretroviral regimens |
| CHER | Children with HIV Early Antiretroviral Therapy |
| D2EFT | Dolutegravir and Darunavir Evaluation in Adults Failing Therapy |
| DolPHIN-2 | Dolutegravir in Pregnant HIV Mothers and Their Neonates |
| DRIVE-AHEAD | Comparison of Doravirine, Tenofovir, Lamivudine (MK-1439A) and ATRIPLA™ in Treatment-Naive Human Immunodeficiency Virus Type 1 (HIV-1)-Infected Participants |
| DRIVE-FORWARD | Safety and Efficacy of Doravirine (MK-1439) in Participants With Human Immunodeficiency Virus 1 (HIV-1) |
| DRIVE-SHIFT | Safety and Efficacy of a Switch to Doravirine, Tenofovir, Lamivudine (MK-1439A) in Human Immunodeficiency Virus (HIV-1)-Infected Participants Virologically Suppressed on an Anti-retroviral Regimen in Combination With Two Nucleoside Reverse Transcriptase Inhibitors |
| ECHO | Evidence for Contraceptive Options and HIV Outcomes |
| ENCORE | Evaluation of Novel Concepts in Optimization of antiRetroviral Efficacy |
| EPIICAL | Early-treated Perinatally HIV-infected Individuals: Improving Children’s Actual Life with Novel Immunotherapeutic Strategies |
| EPPICC | European Pregnancy and Paediatric Infections Cohort Collaboration |
| FLAIR | First Long-Acting Injectable Regimen |
| GEMINI-1 and GEMINI-2 | Efficacy, Safety, and Tolerability Study Comparing Dolutegravir Plus Lamivudine With Dolutegravir Plus Tenofovir/Emtricitabine in Treatment naive HIV Infected Subjects |
| HPTN | HIV Prevention Trials Network |
| IeDEA-SA | International Epidemiology Databases to Evaluate AIDS Southern Africa |
| IMPAACT | International Maternal Pediatric Adolescent AIDS Clinical Trials |
| LATTITUDE | Long-Acting Therapy to Improve Treatment Success in Daily LifE |
| MOCHA | More Options for Children and Adolescents |
| NADIA | Nucleosides And Darunavir/Dolutegravir in Africa |
| NEVEREST | Nevirapine Resistance Study |
| ODYSSEY | Once-daily DTG based ART in Young people vs. Standard thErapY |
| OPERA | Observational Pharmaco-Epidemiology Research & Analysis Database |
| PACTG | Pediatric AIDS Clinical Trials Group |
| PAINT | Pediatric Study in Adolescents Investigating a New NNRTI TMC278 |
| PENPACT | Trial run in collaboration between PENTA and PACTG/IMPAACT |
| PENTA | Paediatric European Network for Treatment of AIDS |
| PETITE | PharmacokinEtics and safeTy of DolutegravIr in neonaTEs |
| PHACS | Pediatric HIV/AIDS Cohort Study |
| PIANO | Paediatric study of Intelence As an NNRTI Option |
| PREDICT | Early Versus Deferred Antiretroviral Therapy for Children Older Than 1 Year Infected with HIV |
| PROMISE | Promoting Maternal and Infant Survival Everywhere Study |
| PROMOTE | PEPFAR PROMise Ongoing Treatment Evaluation |
| PURPOSE-1 | Pre-Exposure Prophylaxis Study of Lenacapavir and Emtricitabine/Tenofovir Alafenamide in Adolescent Girls and Young Women at Risk of HIV Infection |
| PURPOSE-2 | Study of Lenacapavir for HIV Pre-Exposure Prophylaxis in People Who Are at Risk for HIV Infection |
| SALSA | Regimen Switch to Dolutegravir/Lamivudine Fixed Dose Combination From Current Antiretroviral Regimen in HIV-1 Infected and Virologically Suppressed Adults |
| SBIRT | Screening, Brief Intervention, and Referral to Treatment |
| SMILE | Strategy for Maintenance of HIV Suppression with Once Daily Integrate Inhibitor+Darunavir/Ritonavir in Children |
| SOLAR | A Study to Evaluate Efficacy and Safety of Cabotegravir (CAB) Long Acting (LA) Plus (+) Rilpivirine (RPV) LA Versus BIKTARVY® (BIK) in Participants With Human Immunodeficiency Virus (HIV)-1 Who Are Virologically Suppressed |
| START | Strategic Timing of AntiRetroviral Treatment |
| SWORD-1 and SWORD-2 | Regimen Switch to Dolutegravir + Rilpivirine from Current Antiretroviral Regimen in Human Immunodeficiency Virus Type 1 Infected and Virologically Suppressed Adults |
| TANGO | Switch Study to Evaluate Dolutegravir Plus Lamivudine in Virologically Suppressed Human Immunodeficiency Virus Type 1 Positive Adults |
| THRIVE | TMC278 against HIV, in a once-daily Regimen Versus Efavirenz |
Download Guidelines
- Section Only PDF (58.06 KB)
- Full Guideline PDF (6.37 MB)
- Recommendations Only PDF (247.86 KB)
- Tables Only PDF (1.05 MB)
- Drug Tables Only PDF (2.4 MB)